Literature DB >> 33176938

Protection against leptospirosis conferred by Mycobacterium bovis BCG expressing antigens from Leptospira interrogans.

Jessica Dorneles1, Andriele Bonemann Madruga1, Amilton Clair Pinto Seixas Neto1, Caroline Rizzi1, Éverton Burlamarque Bettin1, Amanda Silva Hecktheuer1, Clarissa Caetano de Castro2, Cristina Gevehr Fernandes2, Thaís Larré Oliveira1, Odir Antonio Dellagostin3.   

Abstract

Leptospirosis is a zoonotic disease worldwide and caused by the pathogenic spirochetes of the genus Leptospira. Bacterins make up the vaccines used against leptospirosis, but they only succeed in providing short-term and serovar-specific protection. The use of Mycobacterium bovis BCG as a live vaccine vector expressing leptospiral antigens is a promising alternative, particularly due to its adjuvant properties. Four distinct portions P1 (lipL32), P2 (ligAni), P3 (lemA:ligAni) and P4 (lipL32:lemA) of a recombinant chimera composed of the lipL32, lemA and ligANI genes from Leptospira interrogans were cloned individually according to the BioBricks® strategy in the plasmid pUP500/PpAN. These constructs were individually transformed into a BCG Pasteur strain, and protein expression was detected by Western blot. For vaccination, 5 groups of 10 Golden Syrian hamsters were used, aged 4-6 weeks - group 1, rBCG (LipL32); group 2, rBCG (LigAni); group 3, rBCG (LemA:LigAni); group 4, (LipL32:LemA); group 5, wild-type BCG Pasteur (negative control). Two doses containing 106 CFU of rBCG were administered subcutaneously, the challenge was performed with 5 × LD50 of Leptospira interrogans serovar Copenhageni L1-130, and the animals were observed for a 30-day period until the endpoint was reached. Humoral immunity was assessed via indirect ELISA, while renal colonisation was assessed by culture and quantitative real-time PCR. All vaccinated groups were protected against lethal challenge and renal colonisation, in comparison with negative control group (P < 0.05). Recombinant vaccines were not effective at inducing significant humoral immunity, which suggests the induction of cellular immunity - a characteristic of M. bovis BCG. In conclusion, all formulations provide 100% significant protection against leptospirosis in hamsters with no renal colonisation. The use of rBCG as a vaccine vector represents a promising alternative for the control of animal leptospirosis, allowing for protection against clinical signs of leptospirosis and renal colonisation.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BioBricks; Chimera; LemA; LigAni; LipL32; Vectored vaccine

Mesh:

Substances:

Year:  2020        PMID: 33176938     DOI: 10.1016/j.vaccine.2020.10.086

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Identification of Leptospiral Protein Antigens Recognized by WC1+ γδ T Cell Subsets as Target for Development of Recombinant Vaccines.

Authors:  Aline F Teixeira; Alexandria Gillespie; Alehegne Yirsaw; Emily Britton; Janice C Telfer; Ana Lucia Tabet Oller Nascimento; Cynthia L Baldwin
Journal:  Infect Immun       Date:  2021-10-25       Impact factor: 3.609

2.  TonB-dependent receptor epitopes expressed in M. bovis BCG induced significant protection in the hamster model of leptospirosis.

Authors:  Everton B Bettin; Jessica Dorneles; Amanda S Hecktheuer; Andriele B Madruga; Amilton C P Seixas Neto; Alan J A McBride; Thais L Oliveira; André A Grassmann; Odir A Dellagostin
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-11       Impact factor: 4.813

Review 3.  Revisiting the Development of Vaccines Against Pathogenic Leptospira: Innovative Approaches, Present Challenges, and Future Perspectives.

Authors:  Giovana C Barazzone; Aline F Teixeira; Bruna O P Azevedo; Deborah K Damiano; Marcos P Oliveira; Ana L T O Nascimento; Alexandre P Y Lopes
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

Review 4.  Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis.

Authors:  Reginaldo G Bastos; Heba F Alzan; Vignesh A Rathinasamy; Brian M Cooke; Odir A Dellagostin; Raúl G Barletta; Carlos E Suarez
Journal:  Vaccines (Basel)       Date:  2022-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.